Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LUIS JODAR, PH.D., FORMER PFIZER CHIEF MEDICAL OFFICER FOR VACCINES AND INFECTIOUS DISEASES WITH EXTENSIVE LEADERSHIP EXPERIENCE ACROSS CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS FOR PNEUMOCOCCAL CONJUGATE VACCINES PREVNAR 13 AND PREVNAR 20, JOINS VAXCYTE AS CHIEF MEDICAL OFFICER

VAXCYTE APPOINTS CHIEF MEDICAL OFFICER AND CHIEF LEGAL OFFICER; NARROWS GUIDANCE FOR EXPECTED VAX-31 OPUS-1 TOPLINE DATA

SAN CARLOS, CALIF., AUG. 27, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN FIRESIDE CHATS AND HOST ONE-ON-ONE MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES:

VAXCYTE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM VAX-31 ADULT PHASE 3 OPUS-1 TRIAL EXPECTED IN FOURTH QUARTER OF 2026; OPUS-2 AND OPUS-3 PHASE 3 RESULTS EXPECTED IN FIRST HALF OF 2027 TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PRIMARY IMMUNIZATION SERIES AND BOOSTER DOSE OF VAX-31 INFANT PHASE 2 DOSE-FINDING STUDY EXPECTED EITHER SEQUENTIALLY OR TOGETHER BY END OF FIRST HALF OF 2027 COMPANY INITIATED PHASE 1 STUDY EVALUATING VAX-A1 FOR THE PREVENTION OF DISEASE CAUSED BY GROUP A STREPTOCOCCUS IN HEALTHY ADULTS; TOPLINE DATA EXPECTED IN SECOND HALF OF 2027 APPROXIMATELY $2.5 BILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE30, 2026 SAN CARLOS, CALIF., AUG. 05, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A BUSINESS UPDATE.

VAXCYTE REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN CARLOS, CALIF., JULY 08, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN AND HOST ONE-ON-ONE MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES:

FIRST-IN-HUMAN STUDY EVALUATING VAX-A1, A POTENTIAL BEST-IN-CLASS VACCINE CANDIDATE DESIGNED TO PROVIDE BROAD PROTECTION AGAINST DISEASE CAUSED BY GROUP A STREPTOCOCCUS

VAXCYTE DOSES FIRST PARTICIPANT IN PHASE 1 STUDY EVALUATING VAX-A1 FOR THE PREVENTION OF DISEASE CAUSED BY GROUP A STREPTOCOCCUS IN HEALTHY ADULTS

ENROLLMENT NOW COMPLETED FOR OPUS-1, OPUS-2 AND OPUS-3 PHASE 3 TRIALS EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS

VAXCYTE REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN CARLOS, CALIF., APRIL 07, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON TUESDAY, APRIL 14, 2026 AT 2:15 P.M. ET / 11:15 A.M. PT.

VAXCYTE TO PRESENT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

OPUS-1 PHASE 3 STUDY DESIGNED TO ESTABLISH A NEW STANDARD FOR ADULT PNEUMOCOCCAL CONJUGATE VACCINES (PCVS) THROUGH HEAD-TO-HEAD SAFETY, TOLERABILITY AND IMMUNOGENICITY COMPARISONS OF VAX-31 WITH CAPVAXIVE (PCV21) AND PREVNAR 20 (PCV20), THE CURRENT STANDARD-OF-CARE PCVS

VAXCYTE COMPLETES ENROLLMENT OF OPUS-1 AND OPUS-2 PHASE 3 TRIALS EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS

BASED ON THE STRENGTH OF UNPRECEDENTED RESULTS FROM THE POSITIVE PHASE 1/2 STUDY IN ADULTS AGED 50 AND OLDER, VAXCYTE ADVANCED VAX-31 HIGH DOSE INTO COMPREHENSIVE PHASE 3 ADULT PROGRAM; TOPLINE DATA FROM THE OPUS-1 PIVOTAL NONINFERIORITY TRIAL EXPECTED IN THE FOURTH QUARTER OF 2026

POSITIVE VAX-31 PHASE 1/2 ADULT DATA PUBLISHED IN THE LANCET INFECTIOUS DISEASES HIGHLIGHT BEST-IN-CLASS POTENTIAL OF VAXCYTE'S 31-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) CANDIDATE

COMPREHENSIVE VAX-31 ADULT PHASE 3 CLINICAL PROGRAM, FINALIZED IN CONSULTATION AND ALIGNMENT WITH FDA, ADVANCES WITH THREE PHASE 3 STUDIES UNDERWAY TO SUPPORT PLANNED BLA SUBMISSION TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM OPUS-1 EXPECTED IN FOURTH QUARTER OF 2026; OPUS-2 AND OPUS-3 RESULTS EXPECTED IN FIRST HALF OF 2027 ENROLLMENT COMPLETED IN VAX-31 INFANT PHASE 2 DOSE-FINDING STUDY; TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PRIMARY IMMUNIZATION SERIES AND BOOSTER DOSE EXPECTED EITHER SEQUENTIALLY OR TOGETHER BY END OF FIRST HALF OF 2027 COMPANY ADVANCING EARLY-STAGE PIPELINE, EXPECTS TO INITIATE PHASE 1 ADULT CLINICAL STUDY FOR VAX-A1, A VACCINE CANDIDATE TO PREVENT GROUP A STREP, IN 2026 COMPANY ADVANCES GLOBAL AND U.S. MANUFACTURING CAPABILITIES TO SUPPORT COMMERCIALIZATION OF PNEUMOCOCCAL CONJUGATE VACCINES WITH COMPLETION OF DEDICATED LONZA FACILITY AND INITIATION OF NORTH CAROLINA FILL-FINISH LINE BUILDOUT APPROXIMATELY $2.4 BILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DECEMBER31, 2025 ; EXCLUDES APPROXIMATELY $600.2 MILLION IN NET PROCEEDS FROM FEBRUARY 2026 EQUITY OFFERING COMPANY TO HOST WEBCAST/CONFERENCE CALL TODAY AT 4:30 P.M. ET / 1:30 P.M.

Vaxcyte, Inc.

PCVX

Price

Financial Reports

No items found.

Press Releases

Vaxcyte, Inc.

PCVX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PCVX